Prediction of risk for hepatocellular carcinoma by response of serum α‐fetoprotein to entecavir therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1440-1746|30|7|1175-1182

ISSN： 0815-9319

Source： JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.30, Iss.7, 2015-07, pp. : 1175-1182

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Evaluation of Pancreatitis-Associated Protein as a Serum Marker of Hepatocellular Carcinoma: Comparison with α-Fetoprotein

By  

Oncology, Vol. 55, Iss. 5, 1998-08 ,pp. : 421-425

Karger

Access to resources Recommend Favorite

Early Decrease in α-Fetoprotein, but Not Des-γ-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 251-258

Karger

Access to resources Recommend Favorite

Highly Sensitive Lens culinaris Agglutinin-Reactive α-Fetoprotein: A New Tool for the Management of Hepatocellular Carcinoma

By  

Oncology, Vol. 81, Iss. 1, 2011-12 ,pp. : 61-65

Karger

Access to resources Recommend Favorite

Evaluation of the mRECIST and α-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 192-200

Karger

Access to resources Recommend Favorite

Favorable α‐fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 3, 2010-03 ,pp. : 605-612

John Wiley & Sons Inc

Access to resources Recommend Favorite